Abstract
Transmembrane-4 L-six family member-1 (TM4SF1) is a small plasma membrane glycoprotein that regulates cell motility and proliferation. TM4SF1 is an attractive cancer target because of its high expression in both tumor cells and on the vascular endothelial cells lining tumor blood vessels. We generated mouse monoclonal antibodies against human TM4SF1 in order to evaluate their therapeutic potential; 13 of the antibodies we generated reacted with extracellular loop-2 (EL2), TM4SF1’s larger extracellular, lumen-facing domain. However, none of these antibodies reacted with mouse TM4SF1, likely because the EL2 of mouse TM4SF1 differs significantly from that of its human counterpart. Therefore, to test our antibodies in vivo, we employed an established model of engineered human vessels in which human endothelial colony-forming cells (ECFC) and human mesenchymal stem cells (MSC) are incorporated into Matrigel plugs that are implanted subcutaneously in immunodeficient nude mice. We modified the original protocol by (1) preculturing human ECFC on laminin, fibronectin, and collagen-coated plates, and (2) increasing the ECFC/MSC ratio. These modifications significantly increased the human vascular network in Matrigel implants. Two injections of one of our anti-TM4SF1 EL2 monoclonal antibodies, 8G4, effectively eliminated the human vascular component present in these plugs; they also abrogated human PC3 prostate cancer cells that were incorporated into the ECFC/MSC Matrigel mix. Together, these studies provide a mouse model for assessing tumor xenografts that are supplied by a human vascular network and demonstrate that anti-TM4SF1 antibodies such as 8G4 hold promise for cancer therapy.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Folkman J (1971) Tumor angiogenesis: therapeutic implications. N Engl J Med 285(21):1182–1186
Ferrara N (2002) Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: therapeutic implications. Semin Oncol 29(6 Suppl 16):10–14
Sitohy B, Nagy JA, Dvorak HF (2012) Anti-VEGF/VEGFR therapy for cancer: reassessing the target. Cancer Res 72(8):1909–1914. doi:10.1158/0008-5472.CAN-11-3406
Hellstrom I, Horn D, Linsley P, Brown JP, Brankovan V, Hellstrom KE (1986) Monoclonal mouse antibodies raised against human lung carcinoma. Cancer Res 46(8):3917–3923
O’Donnell RT, DeNardo SJ, Shi XB, Mirick GR, DeNardo GL, Kroger LA, Meyers FJ (1998) L6 monoclonal antibody binds prostate cancer. Prostate 37(2):91–97
Marken JS, Schieven GL, Hellstrom I, Hellstrom KE, Aruffo A (1992) Cloning and expression of the tumor-associated antigen L6. Proc Natl Acad Sci USA 89(8):3503–3507
Shih SC, Zukauskas A, Li D, Liu G, Ang LH, Nagy JA, Brown LF, Dvorak HF (2009) The L6 protein TM4SF1 is critical for endothelial cell function and tumor angiogenesis. Cancer Res 69(8):3272–3277. doi:10.1158/0008-5472.CAN-08-4886
Zukauskas A, Merley A, Li D, Ang LH, Sciuto TE, Salman S, Dvorak AM, Dvorak HF, Jaminet SC (2011) TM4SF1: a tetraspanin-like protein necessary for nanopodia formation and endothelial cell migration. Angiogenesis 14(3):345–354. doi:10.1007/s10456-011-9218-0
Melero-Martin JM, De Obaldia ME, Kang SY, Khan ZA, Yuan L, Oettgen P, Bischoff J (2008) Engineering robust and functional vascular networks in vivo with human adult and cord blood-derived progenitor cells. Circ Res 103(2):194–202
Lin RZ, Moreno-Luna R, Zhou B, Pu WT, Melero-Martin JM (2012) Equal modulation of endothelial cell function by four distinct tissue-specific mesenchymal stem cells. Angiogenesis 15(3):443–455. doi:10.1007/s10456-012-9272-2
Hoffmann J, Schirner M, Menrad A, Schneider MR (1997) A highly sensitive model for quantification of in vivo tumor angiogenesis induced by alginate-encapsulated tumor cells. Cancer Res 57(17):3847–3851
Lin CI, Lau CY, Li D, Jaminet SC (2014) Nanopodia-thin, fragile membrane projections with roles in cell movement and intercellular interactions. J Vis Exp 86:e51320–e51325
Drake AW, Klakamp SL (2007) A rigorous multiple independent binding site model for determining cell-based equilibrium dissociation constants. J Immunol Methods 318(1–2):147–152. doi:10.1016/j.jim.2006.08.015
Wada Y, Li D, Merley A, Zukauskas A, Aird WC, Dvorak HF, Shih SC (2010) A multi-gene transcriptional profiling approach to the discovery of cell signature markers. Cytotechnology 63(1):25–33
Sato K, Aoki J, Misawa N, Daikoku E, Sano K, Tanaka Y, Koyanagi Y (2008) Modulation of human immunodeficiency virus type 1 infectivity through incorporation of tetraspanin proteins. J Virol 82(2):1021–1033. doi:10.1128/JVI.01044-07
Hughes CS, Postovit LM, Lajoie GA (2010) Matrigel: a complex protein mixture required for optimal growth of cell culture. Proteomics 10(9):1886–1890. doi:10.1002/pmic.200900758
Lopez AF, Strath M, Sanderson CJ (1983) Mouse immunoglobulin isotypes mediating cytotoxicity of target cells by eosinophils and neutrophils. Immunology 48(3):503–509
Herlyn D, Herlyn M, Steplewski Z, Koprowski H (1985) Monoclonal anti-human tumor antibodies of six isotypes in cytotoxic reactions with human and murine effector cells. Cell Immunol 92(1):105–114
Clynes RA, Towers TL, Presta LG, Ravetch JV (2000) Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med 6(4):443–446. doi:10.1038/74704
Hellstrom I, Beaumier PL, Hellstrom KE (1986) Antitumor effects of L6, an IgG2a antibody that reacts with most human carcinomas. Proc Natl Acad Sci USA 83(18):7059–7063
Liu AY, Robinson RR, Hellstrom KE, Murray ED Jr, Chang CP, Hellstrom I (1987) Chimeric mouse-human IgG1 antibody that can mediate lysis of cancer cells. Proc Natl Acad Sci USA 84(10):3439–3443
Fell HP, Gayle MA, Yelton D, Lipsich L, Schieven GL, Marken JS, Aruffo A, Hellstrom KE, Hellstrom I, Bajorath J (1992) Chimeric L6 anti-tumor antibody. Genomic construction, expression, and characterization of the antigen binding site. J Biol Chem 267(22):15552–15558
Goodman GE, Hellstrom I, Brodzinsky L, Nicaise C, Kulander B, Hummel D, Hellstrom KE (1990) Phase I trial of murine monoclonal antibody L6 in breast, colon, ovarian, and lung cancer. J Clin Oncol 8(6):1083–1092
Richman CM, DeNardo SJ, O’Grady LF, DeNardo GL (1995) Radioimmunotherapy for breast cancer using escalating fractionated doses of 131I-labeled chimeric L6 antibody with peripheral blood progenitor cell transfusions. Cancer Res 55(23 Suppl):5916s–5920s
DeNardo SJ, Kukis DL, Kroger LA, O’Donnell RT, Lamborn KR, Miers LA, DeNardo DG, Meares CF, DeNardo GL (1997) Synergy of Taxol and radioimmunotherapy with yttrium-90-labeled chimeric L6 antibody: efficacy and toxicity in breast cancer xenografts. Proc Natl Acad Sci USA 94(8):4000–4004
Gerber HP, Koehn FE, Abraham RT (2013) The antibody-drug conjugate: an enabling modality for natural product-based cancer therapeutics. Nat Prod Rep 30(5):625–639. doi:10.1039/c3np20113a
Acknowledgments
We thank Dr Ruei-Zeng Lin for teaching the Matrigel implantation, Kelly Seidl for capturing confocal image, and Andrew Zukauskas for participating in hybridoma screening. This work was supported by NIH Grant P01 CA92644 and by a contract from the National Foundation for Cancer Research.
Author information
Authors and Affiliations
Corresponding authors
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Lin, CI., Merley, A., Sciuto, T.E. et al. TM4SF1: a new vascular therapeutic target in cancer. Angiogenesis 17, 897–907 (2014). https://doi.org/10.1007/s10456-014-9437-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10456-014-9437-2